We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amneal Pharmaceuticals (AMRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amneal Pharmaceuticals is a member of the Medical sector. This group includes 961 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 8.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, AMRX has moved about 31.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 2.6%. This means that Amneal Pharmaceuticals is outperforming the sector as a whole this year.
Another stock in the Medical sector, ANIXA BIOSCIENCES INC (ANIX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 46.1%.
For ANIXA BIOSCIENCES INC, the consensus EPS estimate for the current year has increased 7.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 147 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have gained 13% this year, meaning that AMRX is performing better in terms of year-to-date returns.
On the other hand, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry. This 472-stock industry is currently ranked #73. The industry has moved +9% year to date.
Investors interested in the Medical sector may want to keep a close eye on Amneal Pharmaceuticals and ANIXA BIOSCIENCES INC as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amneal Pharmaceuticals (AMRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amneal Pharmaceuticals is a member of the Medical sector. This group includes 961 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 8.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, AMRX has moved about 31.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 2.6%. This means that Amneal Pharmaceuticals is outperforming the sector as a whole this year.
Another stock in the Medical sector, ANIXA BIOSCIENCES INC (ANIX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 46.1%.
For ANIXA BIOSCIENCES INC, the consensus EPS estimate for the current year has increased 7.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 147 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have gained 13% this year, meaning that AMRX is performing better in terms of year-to-date returns.
On the other hand, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry. This 472-stock industry is currently ranked #73. The industry has moved +9% year to date.
Investors interested in the Medical sector may want to keep a close eye on Amneal Pharmaceuticals and ANIXA BIOSCIENCES INC as they attempt to continue their solid performance.